EDAP TMS S.A. (EDAP)
| Market Cap | 268.10M |
| Revenue (ttm) | 50.46M |
| Net Income (ttm) | 1.70M |
| Shares Out | 29.02M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | 23.53 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $9.10 |
| Previous Close | $9.54 |
| Change ($) | -0.44 |
| Change (%) | -4.61% |
| Day's Open | 9.25 |
| Day's Range | 8.83 - 9.50 |
| Day's Volume | 416,017 |
| 52-Week Range | 1.46 - 10.68 |
LYON, France, January 19, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that Marc Oczachowski, President and CEO, wil...
LYON, France, January 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today positive 24 month interim results from the “H...
EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Recaps progress made in 2020 notwithstanding the ongoing COVID-19 pandemic and previews anticipated 2021 milestones
LYON, France, January 5, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that it will participate in the 10th Annual Li...
LYON, France, December 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy- based therapies, announced today two new Focal One sales to leading U.S. hea...
Final rules establish, for the first time, a Category 1 CPT code and reimbursement to physicians performing ablation of malignant prostate tissue with HIFU in the US
EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q3 2020 Results - Earnings Call Transcript
Shares of Edap TMS (NASDAQ:EDAP) were flat after the company reported Q3 results. Quarterly Results Earnings per share decreased 233.33% over the past year to ($0.04), which missed the estimat...
Generated strongest total revenue quarter of 2020
LYON, France, November 17, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive dis...
LYON, France, November 10, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual ...
Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDT
Knifeless Surgery: Prospects And Competition For EDAP
As of late, it has definitely been a great time to be an investor in EDAP TMS.
The company offers an innovative device that produces non-invasive HIFA treatment for prostate cancer with other applications to follow.
Call to be Held Tuesday, September 22nd @ 8am Eastern Time
As of late, it has definitely been a great time to be an investor EDAP TMS.
LYON, France, September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virt...
EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q2 2020 Results - Earnings Call Transcript
LYON, France, August 26, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the second quarter of 20...
LYON, France, August 25, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company has received approval from Fr...
Company to host conference call and webcast on Thursday, August 27 at 8:30 am EDT
Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focus...
EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
LYON, France, July 15, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent sales successes that occurred...
LYON, France, June 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announced today that veteran medical technology executive Marie...
LYON, France, May 28, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announced today the appointment of Frank Van Hyfte as Vice Presid...
EDAP Shares Are Still A Steal, But The Pandemic Could Be A Wrench
EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q1 2020 Results - Earnings Call Transcript
LYON, France, May 13, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the first quarter of 2020 a...
LYON, France, May 12, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive worldwid...
EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2019 Results - Earnings Call Transcript
LYON, France, March 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today financial results for the fourth quarter and fu...
LYON, France, March 17, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:
LYON, France, February 18, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company recently showcased its Focal...
EDAP Announces Sale of Robotic Focal One® HIFU Device to University of Miami
Recaps significant progress made in 2019 and previews expectations for accelerating global growth in 2020
Study confirms feasibility of using Focal One HIFU to treat rectal endometriosis
LYON, France, November 26, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today that the first Focal One® treatment was performed at...
EDAP TMS S.A. (EDAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q3 2019 Results - Earnings Call Transcript
LYON, France, November 13, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today financial results for the third quarter and nine mon...
The company is in the first inning with its HIFU treatment of prostate cancer, enjoying near triple-rate growth in Q2.
As of late, it has definitely been a great time to be an investor EDAP TMS.
Top Ranked Momentum Stocks to Buy for September 20th
As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q2 2019 Results - Earnings Call Transcript
About EDAP
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided r... [Read more...]
| Industry Medical Devices | IPO Date Jul 31, 1997 |
| CEO Marc Oczachowski | Employees 216 |
| Stock Exchange NASDAQ | Ticker Symbol EDAP |
Analyst Forecasts
According to 2 analysts, the average rating for EDAP TMS S.A. stock is "Buy." The 12-month stock price forecast is 12.67, which is an increase of 39.23% from the latest price.